Chemotherapy Induced Pain Epidemiology Forecast
Key Highlights
- As per Burgess et al. (2021), the prevalence of Chemotherapy-Induced Peripheral Neuropathy one month after finishing chemotherapy approaches 68%, and persists in approximately one third of patients beyond 6 months.
- According to Coffeen et al. (2019), Chemotherapy-Induced Peripheral Neuropathy is present in up to 68.1% of the patients within 1 month of receiving Chemotherapy and about 30% may still be presenting symptoms 6 months after treatment discontinuation.
- Chemotherapy-Induced Pain epidemiology is segmented as Total Incident Cases of Chemotherapy-Induced Pain, Diagnosed and Treatable Cases of Chemotherapy-Induced Neuropathic Pain, and Total Prevalence of Chemotherapy-Induced Neuropathic Pain based on Duration Post-Chemotherapy] in the Chemotherapy-Induced Pain epidemiology report.
Request for unlocking CAGR of Chemotherapy-Induced Pain Epidemiology
DelveInsight's ‘Chemotherapy-Induced Pain — Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy-Induced Pain epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Chemotherapy-Induced Pain Epidemiology Disease Understanding
The DelveInsight’s Chemotherapy-Induced Pain market report gives a thorough understanding of Chemotherapy-Induced Pain by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Chemotherapy-induced peripheral neuropathy is a disabling pain condition resulting from chemotherapy for cancer. Peripheral neuropathy usually manifests as painful symptoms, characterizing a neuropathic pain syndrome. Moreover, observed symptoms vary in intensity and duration and range from acute, transient thermal sensations to permanent changes in peripheral nerves accompanied by chronic pain and irreversible nerve damage.
The symptoms range from early post-treatment pain, such as the paclitaxel acute pain syndrome (P-APS), to paraesthesias, sensory ataxia, and mechanical and cold allodynia. The extremities of the body are predominantly affected, but the pain can proceed along the limbs during repetitive treatment. Substances that cause Chemotherapy-induced peripheral neuropathy pain include the commonly used taxanes, platinum derivatives and vinca alkaloids, as well as the more rarely used ixabepilone, bortezomib and thalidomide. In addition chemotherapy-induced pain and sensory abnormalities may persist for months or even years after the cessation of chemotherapy. Moreover, painful sensations, including spontaneous burning, shooting or electric shock-like pain as well as mechanical or thermal allodynia or hyperalgesia frequently occur.
Chemotherapy-Induced Pain Diagnosis
Electrodiagnostic methods are considered the reference standard for the functional assessment of large sensory and motor fibers which drive paraesthesia, numbness and weakness seen in people with Chemotherapy-Induced Pain. Although sensory testing used in composite scoring systems is often deployed in the clinical setting, a rigorous, lengthy battery of standardized sensory tests is required to reliably identify a patient’s sensory phenotype.
Chemotherapy-Induced Pain Epidemiology
The Chemotherapy-Induced Pain epidemiology section provides insights about historical and current Chemotherapy-Induced Pain patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
- As per Burgess et al. (2021), the prevalence of Chemotherapy-Induced Peripheral Neuropathy one month after finishing chemotherapy approaches 68%, and persists in approximately one third of patients beyond 6 months.
- According to Coffeen et al. (2019), Chemotherapy-Induced Peripheral Neuropathy is present in up to 68.1% of the patients within 1 month of receiving Chemotherapy and about 30% may still be presenting symptoms 6 months after treatment discontinuation.
- The disease epidemiology covered in the report provides historical as well as forecasted Chemotherapy-Induced Pain epidemiology [segmented as Total Incident Cases of Chemotherapy-Induced Pain, Diagnosed and Treatable Cases of Chemotherapy-Induced Neuropathic Pain, and Total Prevalence of Chemotherapy-Induced Neuropathic Pain based on Duration Post-Chemotherapy] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.
Country Wise- Chemotherapy-Induced Pain Epidemiology
This section provides glimpse of the Chemotherapy-Induced Pain epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
KOL- Views
To keep up with the current Chemotherapy-Induced Pain patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Chemotherapy-Induced Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Chemotherapy-Induced Pain Epidemiology Report
- The report covers the descriptive overview of Chemotherapy-Induced Pain, explaining their causes, symptoms, pathophysiology, and genetic basis
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
- The repor
- sesses the disease risk and burden and highlights the unmet needs of Chemotherapy-Induced Pain
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population
- The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Chemotherapy-Induced Pain, Diagnosed and Treatable Cases of Chemotherapy-Induced Neuropathic Pain, and Total Prevalence of Chemotherapy-Induced Neuropathic Pain based on Duration Post-Chemotherapy
Chemotherapy-Induced Pain Epidemiology Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy-Induced Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chemotherapy-Induced Pain
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Learn how the therapeutic market will evolve and grow in the coming years: Chemotherapy-Induced Pain Market
Chemotherapy-Induced Pain Report Insights
- Patient Population
- Therapeutic Approaches
Chemotherapy-Induced Pain Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Chemotherapy-Induced Pain Epidemiology Segmentation
Chemotherapy-Induced Pain Report Assessment
- Disease Understanding
- Current Diagosis Practices and Guidelines
- Epidemiology Trends
Key Questions
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Chemotherapy-Induced Pain?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Chemotherapy-Induced Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Chemotherapy-Induced Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Chemotherapy-Induced Pain?
- Out of all 7MM countries, which country would have the highest prevalent population of Chemotherapy-Induced Pain during the forecast period (2025-2034)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Chemotherapy-Induced Pain Disease market
- To understand the future market competition in the Chemotherapy-Induced Pain Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Pain Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Chemotherapy-Induced Pain Disease market
- To understand the future market competition in the Chemotherapy-Induced Pain Disease market
